MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance
CTA Filing in Late December 2010 Represented the Eighth Clinical Milestone Last Year
Advertisement
MorphoSys AG announced that it has received a clinical milestone payment from Boehringer Ingelheim in connection with the regulatory filing of a clinical trial application for a phase 1 trial of a HuCAL-derived antibody. The filing took place in late December 2010 making this the eighth clinical milestone met with partners during the year. Financial details are not disclosed.
"In 2010, we saw eight clinical milestones reached with five different partners which surpassed our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks the start of the first clinical program within our partnership with Boehringer Ingelheim."
MorphoSys's clinical pipeline now comprises ten partnered programs in Phase 1 and five in Phase 2 development as well as the Company's proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous